Post-progression survival and progression-free survival in patients with advanced hepatocellular carcinoma treated by sorafenib-Reference-Cited by-同舟云学术

Post-progression survival and progression-free survival in patients with advanced hepatocellular carcinoma treated by sorafenib

Published:2015-11-02 Issue:7 Volume:46 Page:650-656
ISSN:1386-6346
Container-title:Hepatology Research
language:en
Short-container-title:Hepatol Res

Author:

Terashima Takeshi¹,Yamashita Tatsuya¹,Takata Noboru¹,Nakagawa Hidetoshi¹,Toyama Tadashi²,Arai Kuniaki¹,Kitamura Kazuya¹,Yamashita Taro¹,Sakai Yoshio¹,Mizukoshi Eishiro¹,Honda Masao¹,Kaneko Shuichi¹

Affiliation:

1. Departments of Gastroenterology; Kanazawa University Hospital; Kanazawa Japan

2. Department of Nephrology; Kanazawa University Hospital; Kanazawa Japan

Publisher

Wiley

Subject

Infectious Diseases,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/hepr.12601/fullpdf

Reference33 articles.

1. Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer;Hayashi;Ann Oncol,2012

2. Postprogression survival for first-line chemotherapy in patients with advanced gastric cancer;Kawakami;Eur J Cancer,2013

3. Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer;Petrelli;Ann Oncol,2013

4. Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials;Saad;J Clin Oncol,2010

5. Detecting an overall survival benefit that is derived from progression-free survival;Broglio;J Natl Cancer Inst,2009

Cited by 72 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessment of Macrovascular Invasion in Advanced Hepatocellular Carcinoma: Clinical Implications and Treatment Outcomes with Systemic Therapy;Liver Cancer;2024-05-21

2. Clinical usefulness of newly developed prognostic predictive score for atezolizumab plus bevacizumab for hepatocellular carcinoma;Cancer Reports;2024-04

3. Dual specific phosphatase 4 suppresses ferroptosis and enhances sorafenib resistance in hepatocellular carcinoma;Drug Resistance Updates;2024-03

4. Comparative analysis of the therapeutic outcomes of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma patients aged 80 years and older: Multicenter study;Hepatology Research;2023-12-06

5. Impact of post‐progression survival in second‐line treatment with molecular target agents for unresectable hepatocellular carcinoma;Hepatology Research;2023-11-04